Optinose Shared Additional Encouraging Data From Late-Stage Chronic Sinusitis Studies

Optinose Inc  (NASDAQ: OPTN ) has announced additional results  from the ReOpen trial program evaluating XHANCE for chronic sinusitis.  XHANCE (fluticasone propionate) nasal spray is a drug-device combination product combining its proprietary Exhalation Delivery System (EDS) designed to deliver the drug high and deep in nasal passages with an anti-inflammatory ... Full story available on Benzinga.com